Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review)

作者：Khasayeva M A^*; Gorokhova T V; Boyko A N; Gusev E I

来源：Zhurnal Nevrologii i Psikhiatrii Imeni S S Korsakova, 2013, 113(2): 87-+.

• alemtuzumab
• monoclonal antibodies
• multiple sclerosis
• CD52 antigen

Recently published results of II and III phase clinical trials of alemtuzumab in relapsing-remitting multiple sclerosis (MS) are reviewed. This drug has an immunosuppressive mechanism of action with an anti-inflammatory effect higher than that of high-dose beta-interferon. Its neuroprotective activity and possible side-effects are discussed.

• 出版日期2013